“a nonsignificant trend”

There was a nonsignificant trend toward fewer patients seen for rhinoconjunctivitis/rhinosinusitis (29.4% vs 32.6%; P = .13).

There was a nonsignificant trend toward worse disability at 9 months in the INH-R category (cumulative OR, 1.44 [95% CI, .90–2.32], P = .13).

28 The application of band‐pass filters to the mean change of the total Montgomery–Asberg Depression Rating Scale scores in this study increased the separation of active drug from placebo and reversed the direction of the original trial outcome (MMRM; P = .58) by generating a nonsignificant trend in a positive direction ( P = .13 and 0.16).

There was a nonsignificant trend toward lower urine protein excretion (ratio: 0.60; 95% CI: 0.31–1.17; P = 0.13) and urinary kidney injury molecule-1 (ratio: 0.85; 95% CI: 0.71–1.02; P = 0.08).

RESULTS There was a nonsignificant trend toward improvement in A1C levels in the intervention group (from unadjusted mean A1C of 8.77 to 8.40%), as compared with usual care (from 8.58 to 8.53%) ( P = 0.131).

When patients with the dark phenotype were compared to the combined group of patients with intermediate and fair phenotypes, there was a nonsignificant trend towards a decreased risk of death for the intermediate/fair phenotypes (HR 0.68, CI 0.42–1.12, p =0.131), but when adjusting for M category, the difference was significant (HR 0.57, CI 0.34–0.93, p =0.026).

There was a nonsignificant trend for worsening IMF:SM over 24 months and lower physical function scores (− 8.76 ± 5.79, p = 0.132).

falciparum infection (incidence rate ratio [IRR] = 1.26; 95% CI = 1.08–1.46; P = 0.004), as well as a nonsignificant trend toward higher parasite density (exponential of the β coefficient [Expβ] = 1.12; 95% CI = 0.96–1.31; P = 0.133) and higher odds of infection over five surveys (odds ratio [OR] = 1.79; 95% CI = 0.89–3.59; P = 0.104).

Other fractures showed a nonsignificant trend toward lower GTOS values relative to long bone fractures (β=-3.48, robust SE=2.32, p=0.133).

In this group, there was a nonsignificant trend favoring adjuvant therapy in terms of RFS (HR 0.53, p = 0.134), though OS benefit was not observed, likely due to the small sample size and limited events.

8 ) while there was a nonsignificant trend for Ptpn13 to be reduced (t (11) = 1.614, p = 0.1348).

[ 10 ] observed events, revealing a nonsignificant trend favoring combination therapy (OR, 0.44 [95% CI, 0.15–1.30]; P =0.136).

Evaluation of pulmonary disease burden using a scoring system designed to discriminate differences between individual macaques with low disease volume revealed a nonsignificant trend ( P = 0.1364) for a reduction in the total CT score in the FIV group compared to the scores attributed to macaques in the unvaccinated group ( Fig. 6D ).

However, in TrialNet, there was a nonsignificant trend (HR 0.696 [95% CI 0.431, 1.22], P = 0.137).

There was a nonsignificant trend toward an interaction between surprise ratings and group, F (1,775) = 2.21, P = 0.137, 95% CI = [−0.071, 0.522], as well as toward a three-way interaction of surprise ratings, group, and reactivation type, F (1,808) = 2.2, P = 0.138, 95% CI = [−0.072, 0.527].

B2 strains exhibited higher virulence scores than non-B2 strains (10.7 ± 2.7 versus 5.8 ± 4.0, P = 0.002), with a nonsignificant trend toward a lower score in B2a than B2b (10.0 ± 2.4 versus 11.5 ± 3.0, P = 0.138) ( Supplemental Figure 2 ).

However, the expression level one of the measured miRNAs, miR378c, showed a nonsignificant trend toward upregulation in response to treatment ( p = 0.138) ( Figure 2 A).

The pooled analysis of four studies 42 45 49 51 found a nonsignificant trend for benefit for routine platelet transfusion when PLT falls below 50 × 10 9 cells/L, with an odds ratio of 0.84 (95% CI, 0.46–1.58, p = 0.139, I 2 = 45.5%).

Fetuses in the high-dose group exhibited markedly lower weight (−0.107 ± 0.040 g, P = 0.016) and crown-rump length (−3.159 ± 0.262 mm, P < 0.001) compared with controls, while the mid-dose group showed a nonsignificant trend for reduced weight (−0.056 ± 0.036 g, P = 0.139) and significantly reduced length (−1.534 ± 0.236 mm, P < 0.001).

There was a nonsignificant trend between loss-of-function and neutral alleles (OR = 0.5, P = 0.14) across the disease status and a similar trend between loss-of-function and gain-of-function alleles (OR = 0.41, P = 0.17; Fig. 5E ).

When comparing the median change in CRP during NAC versus placebo therapy, there was a nonsignificant trend toward a CRP decrease with NAC (−0.18 vs. 0.21 mg/L, p= 0.14).

The E′ value (m/s) in the lateral wall demonstrated a statistically significant increase on probenecid in comparison to placebo ( P =0.01), while the septal wall showed a nonsignificant trend ( P =0.14).

There was a nonsignificant trend towards higher average skilled nursing charges for case-patients ($460 vs. $204 p=0.14); however, the average number of days in a skilled nursing facility was the same for case-patients and controls.

Comparison of outcomes by mRS shift analysis revealed a significant difference between transfer and direct groups for MT alone ( P =0.035) and a nonsignificant trend for IV-tPA ( P =0.14).

However, individuals in the UM/NM group exhibited a nonsignificant trend toward higher odds of nonresponse compared to PM/IM (OR 1.53 [0.88–2.66], p = 0.14).